
The AMR Action Fund enables breakthroughs in antimicrobials. It invests in companies that are developing urgently needed therapeutics for priority pathogens and advocates for market reforms to change how society values these lifesaving drugs. Its aim is to help launch two to four new antimicrobials in the next decade and create a sustainable ecosystem of investment and innovation to take on one of the biggest global health challenges facing the world.